GPC3-CAR-T cell therapy

Drug Profile

GPC3-CAR-T cell therapy

Alternative Names: anti-GPC3 CAR T; CAR T cells redirected to Glypican-3; CAR-GPC3 T-cell; Glypican-3-chimeric-antigen-receptor-T-cell-therapy; GPC3-CAR/CSG-GPC3; KJgpc3 001

Latest Information Update: 10 May 2017

Price : $50

At a glance

  • Originator CARsgen
  • Developer CARsgen; Shanghai Jiao Tong University
  • Class Antineoplastics; CAR-T cell therapies
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; Gene transference; Glypican 3 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Hepatocellular carcinoma
  • Clinical Phase Unknown Breast cancer; Gastric cancer; Lung cancer

Most Recent Events

  • 25 Apr 2017 CARsgen terminates a phase I trial in Hepatocellular carcinoma (In adults, In the elderly, Late-stage disease, Refractory metastatic disease) in China for reason not related to safety, efficacy, feasibility, or funding issues (Parenteral) (NCT02395250)
  • 30 Nov 2016 Clinical trials in Breast cancer (Metastatic disease, Recurrent, Second-line therapy or greater, Late-stage disease) in China (Parenteral) (ChiCTR-OPN16009943)
  • 30 Nov 2016 Clinical trials in Gastric cancer (Recurrent, Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (Parenteral) (ChiCTR-OPN16009943)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top